

ASX/NASDAQ ANNOUNCEMENT

Benitec Biopharma announces participation at the 2017 Cell & Gene Meeting on the Mesa Conference in La Jolla, California

Sydney, Australia, 28 September 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that Dr David Suhy, Chief Scientific Officer, will present at the annual Partnering Forum, part of the “Cell & Gene Meeting on the Mesa” Conference to be held on October 4-6 in La Jolla, California.

This conference is the largest partnering meeting organized specifically for the cell and gene therapy sector, providing excellent opportunities for participants to establish key relationships and accelerate business development.

Benitec’s presentation at the conference will be made at 3:45 pm Pacific Time on October 5, 2017 at the Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037.

A live video webcast of the company presentation will be available on the [Investor Centre](#) section of the Company’s website, <http://www.benitec.com/>, and a copy of the presentation will be posted prior to the event. The webcast replay will be available for 90 days following the live presentation.

The three day conference is organized by Alliance Regenerative Medicine and the Sanford Stem Cell Clinical Center at UC San Diego, and comprises of a two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium. The event’s Partnering Forum on October 4-5, which Benitec are presenting at, features more than 70 dedicated company presentations in addition to 90 panelists and featured speakers.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com

Australia Investor Relations

Market Eye
Orla Keegan
Director
Tel: +61 (2) 8097 1201
Email: orla.keegan@marketeye.com.au

United States Investor Relations

M Group Strategic Communications
Jay Morakis
Managing Director
Tel: +1 212.266.0191
Email: jmorakis@MGroupSC.com



About Benitec Biopharma Limited:

Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including OPMD, head & neck squamous cell carcinoma, retinal based diseases such as wet age-related macular degeneration, and hepatitis B. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain, cancer immunotherapy and retinitis pigmentosa.

Safe Harbor Statement:

This press release contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Any forward-looking statements that may be in the press release are subject to risks and uncertainties relating to the difficulties in Benitec's plans to develop and commercialise its product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec's product candidates, potential future out-licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.